Efficient immune responses against Intimin and EspB of enterohaemorragic Escherichia coli after intranasal vaccination using the TLR2/6 agonist MALP-2 as adjuvant

Vaccine

Volumn 26, Issue 44, 2008, Pages 5662-5667

  Cataldi, Angel ^a   Yevsa, Tetyana ^b   Vilte, Daniel A ^a   Schulze, Kai ^b   Castro Parodi, Mauricio ^c   Larzábal, Mariano ^a   Ibarra, Cristina ^c   Mercado, Elsa C ^a   Guzmán, Carlos A ^b  

^a INSTITUTO NACIONAL DE TECNOLOGÍA AGROPECUARIA INTA   (Argentina)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

EHEC; EspB; Intimin; MALP 2; Mucosal vaccination

Indexed keywords

ESCHERICHIA COLI SECRETED PROTEIN A; ESCHERICHIA COLI SECRETED PROTEIN B; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; INTERLEUKIN 4; INTIMIN; MACROPHAGE ACTIVATING LIPOPEPTIDE 2; RECOMBINANT C280 GAMMA INTIMIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 2 AGONIST; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 6 AGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; ENTEROHEMORRHAGIC ESCHERICHIA COLI; FEMALE; HEMOLYSIS; IMMUNOGENICITY; IMMUNOSTIMULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINE PRODUCTION;

ADHESINS, BACTERIAL; ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; ESCHERICHIA COLI VACCINES; FEMALE; LIPOPEPTIDES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 6; VACCINATION;

EID: 52949113396     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.027     Document Type: Article

References (38)

1. Karch H., Tarr P.I., and Bielaszewska M. Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol 295 October (6/7) (2005) 405-418
2. Repetto H.A. Long-term course and mechanisms of progression of renal disease in hemolytic uremic syndrome. Kidney Int Suppl 97 August (2005) S102-S106
3. Johnson R.P., Cray Jr. W.C., and Johnson S.T. Serum antibody responses of cattle following experimental infection with Escherichia coli O157:H7. Infect Immun 64 May (5) (1996) 1879-1883
4. McDaniel T.K., Jarvis K.G., Donnenberg M.S., and Kaper J.B. A genetic locus of enterocyte effacement conserved among diverse enterobacterial pathogens. Proc Natl Acad Sci USA 92 February (5) (1995) 1664-1668
5. Ghaem-Maghami M., Simmons C.P., Daniell S., Pizza M., Lewis D., Frankel G., et al. Intimin-specific immune responses prevent bacterial colonization by the attaching-effacing pathogen Citrobacter rodentium. Infect Immun 69 September (9) (2001) 5597-5605
6. Lee C.A. Type III secretion systems: machines to deliver bacterial proteins into eukaryotic cells?. Trends Microbiol 5 April (4) (1997) 148-156
7. Jerse A.E., and Kaper J.B. The eae gene of enteropathogenic Escherichia coli encodes a 94-kilodalton membrane protein, the expression of which is influenced by the EAF plasmid. Infect Immun 59 December (12) (1991) 4302-4309
8. Yu J., and Kaper J.B. Cloning and characterization of the eae gene of enterohaemorrhagic Escherichia coli O157:H7. Mol Microbiol 6 February (3) (1992) 411-417
9. Knutton S., Rosenshine I., Pallen M.J., Nisan I., Neves B.C., Bain C., et al. A novel EspA-associated surface organelle of enteropathogenic Escherichia coli involved in protein translocation into epithelial cells. EMBO J 17 8 (1998) 2166-2176
10. Wolff C., Nisan I., Hanski E., Frankel G., and Rosenshine I. Protein translocation into host epithelial cells by infecting enteropathogenic Escherichia coli. Mol Microbiol 28 1 (1998) 143-155
11. Kenny B., DeVinney R., Stein M., Reinscheid D.J., Frey E.A., and Finlay B.B. Enteropathogenic E. coli (EPEC) transfers its receptor for intimate adherence into mammalian cells. Cell 91 November (4) (1997) 511-520
12. Bretschneider G., Berberov E.M., and Moxley R.A. Isotype-specific antibody responses against Escherichia coli O157:H7 locus of enterocyte effacement proteins in adult beef cattle following experimental infection. Vet Immunol Immunopathol 118 August (3/4) (2007) 229-238
13. Potter A.A., Klashinsky S., Li Y., Frey E., Townsend H., Rogan D., et al. Decreased shedding of Escherichia coli O157:H7 by cattle following vaccination with type III secreted proteins. Vaccine 22 January (3/4) (2004) 362-369
14. Judge N.A., Mason H.S., and O'Brien A.D. Plant cell-based intimin vaccine given orally to mice primed with intimin reduces time of Escherichia coli O157:H7 shedding in feces. Infect Immun 72 January (1) (2004) 168-175
15. Dean-Nystrom E.A., Gansheroff L.J., Mills M., Moon H.W., and O'Brien A.D. Vaccination of pregnant dams with intimin(O157) protects suckling piglets from Escherichia coli O157:H7 infection. Infect Immun 70 May (5) (2002) 2414-2418
16. Agin T.S., Zhu C., Johnson L.A., Thate T.E., Yang Z., and Boedeker E.C. Protection against hemorrhagic colitis in an animal model by oral immunization with isogeneic rabbit enteropathogenic Escherichia coli attenuated by truncating intimin. Infect Immun 73 October (10) (2005) 6608-6619
17. Marcato P., Griener T.P., Mulvey G.L., and Armstrong G.D. Recombinant Shiga toxin B-subunit-keyhole limpet hemocyanin conjugate vaccine protects mice from Shigatoxemia. Infect Immun 73 October (10) (2005) 6523-6529
18. Smith M.J., Teel L.D., Carvalho H.M., Melton-Celsa A.R., and O'Brien A.D. Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2. Vaccine 24 May (19) (2006) 4122-4129
19. Bosworth B.T., Samuel J.E., Moon H.W., O'Brien A.D., Gordon V.M., and Whipp S.C. Vaccination with genetically modified Shiga-like toxin IIe prevents edema disease in swine. Infect Immun 64 January (1) (1996) 55-60
20. Capozzo A.V., Pistone Creydt V., Dran G., Fernández G., Gómez S., Bentancor L.V., et al. Development of DNA vaccines against hemolytic-uremic syndrome in a murine model. Infect Immun 71 July (7) (2003) 3971-3978
21. Wen S.X., Teel L.D., Judge N.A., and O'Brien A.D. Genetic toxoids of Shiga toxin types 1 and 2 protect mice against homologous but not heterologous toxin challenge. Vaccine 24 February (8) (2006) 1142-1148
22. van Diemen P.M., Dziva F., Abu-Median A., Wallis T.S., van den Bosch H., Dougan G., et al. Subunit vaccines based on intimin and Efa-1 polypeptides induce humoral immunity in cattle but do not protect against intestinal colonisation by enterohaemorrhagic Escherichia coli O157:H7 or O26:H. Vet Immunol Immunopathol 116 March (1/2) (2007) 47-58
23. Dziva F., Vlisidou I., Crepin V.F., Wallis T.S., Frankel G., and Stevens M.P. Vaccination of calves with EspA, a key colonisation factor of Escherichia coli O157:H7, induces antigen-specific humoral responses but does not confer protection against intestinal colonisation. Vet Microbiol 123 July (1-3) (2007) 254-261
24. Kaufmann A., Muhlradt P.F., Gemsa D., and Sprenger H. Induction of cytokines and chemokines in human monocytes by Mycoplasma fermentans-derived lipoprotein MALP-2. Infect Immun 67 December (12) (1999) 6303-6308
25. Muhlradt P.F., Kiess M., Meyer H., Sussmuth R., and Jung G. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J Exp Med 185 June (11) (1997) 1951-1958
26. Rharbaoui F., Drabner B., Borsutzky S., Winckler U., Morr M., Ensoli B., et al. The mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur J Immunol 32 October (10) (2002) 2857-2865
27. Rharbaoui F., Westendorf A., Link C., Felk S., Buer J., Gunzer M., et al. The mycoplasma-derived macrophage- activating 2-kilodalton lipopeptide triggers global immune activation on nasal mucosa-associated lymphoid tissues. Infect Immun 72 December (12) (2004) 6978-6986
28. Gioffré A., Meichtri L., Miliwebsky E., Baschkier A., Chillemi G., Romano M.I., et al. Detection of Shiga toxin-producing Escherichia coli by PCR in cattle in Argentina. Evaluation of two procedures. Vet Microbiol 87 July (4) (2002) 301-313
29. Mercado E.C., Gioffré A., Rodríguez S.M., Cataldi A., Irino K., Elizondo A.M., et al. Non-O157 Shiga toxin-producing Escherichia coli isolated from diarrhoeic calves in Argentina. J Vet Med B: Infect Dis Vet Public Health 51 March (2) (2004) 82-88
30. Olive C., Schulze K., Sun H.K., Ebensen T., Horváth A., Toth I., et al. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen componentM protein/SfbI lipid core peptide vaccine formulation. Vaccine 25 February (10) (2007) 1789-1797
31. Warawa J., Finlay B.B., and Kenny B. Type III secretion-dependent hemolytic activity of enteropathogenic Escherichia coli. Infect Immun 67 October (10) (1999) 5538-5540
32. Jenkins C., Chart H., Smith H.R., Hartland E.L., Batchelor M., Delahay R.M., et al. Antibody response of patients infected with verocytotoxin-producing Escherichia coli to protein antigens encoded on the LEE locus. J Med Microbiol 49 January (1) (2000) 97-101
33. Karpman D., Bekassy Z.D., Sjogren A.C., Dubois M.S., Karmali M.A., Mascarenhas M., et al. Antibodies to intimin and Escherichia coli secreted proteins A and B in patients with enterohemorrhagic Escherichia coli infections. Pediatr Nephrol 17 March (3) (2002) 201-211
34. Li Y., Frey E., Mackenzie A.M., and Finlay B.B. Human response to Escherichia coli O157:H7 infection: antibodies to secreted virulence factors. Infect Immun 68 September (9) (2000) 5090-5095
35. Becker P.D., Fiorentini S., Link C., Tosti G., Ebensen T., Caruso A., et al. The HIV-1 matrix protein p17 can be efficiently delivered by intranasal route in mice using the TLR 2/6 agonist MALP-2 as mucosal adjuvant. Vaccine 24 June (25) (2006) 5269-5276
36. Borsutzky S., Ebensen T., Link C., Becker P.D., Fiorelli V., Cafaro A., et al. Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant. Vaccine 24 March (12) (2006) 2049-2056
37. Link C., Gavioli R., Ebensen T., Canella A., Reinhard E., and Guzman C.A. The toll-like receptor ligand MALP-2 stimulates dendritic cell maturation and modulates proteasome composition and activity. Eur J Immunol 34 March (3) (2004) 899-907
38. Mundy R., Girard F., FitzGerald A.J., and Frankel G. Comparison of colonization dynamics and pathology of mice infected with enteropathogenic Escherichia coli, enterohaemorrhagic E. coli and Citrobacter rodentium. FEMS Microbiol Lett 265 December (1) (2006) 126-132